Unsubscribe

A message from Crypto 101

Look inside the private offices where billion-dollar crypto moves are made…

And what you see right now is ACTION.

I'm talking about machine learning models designed to predict crypto moves hours before they happen.

Quantum-level market analysis.

Satellite data tracking mining operations.

Social sentiment AI that reads 50 million posts per day.

While you're checking CoinMarketCap, they're looking into the future…

Solana, Ethereum, XRP—we know the funds are investing heavily. But now, we know why.

I've tapped my contacts and convinced 20+ top crypto hedge fund managers to present live to our community.

For the first time, they're holding nothing back…

You'll discover the altcoins they're most excited about (and why).

You'll get the analysis directly from the best to ever do it. (This isn't basic technical analysis. This is financial warfare.)

Expect to discover:

→ AI models and technology predicting altcoin breakouts

→ How $100M positions move markets before you notice

→ The secret derivatives plays generating massive returns

→ Which tokens their algorithms are flagging for Q3

The research costs them millions. The edge is worth billions.

You get it free.

But only if you're one of the first to claim your seat:

Lock in your pass to the Crypto Hedge Fund Summit now.

This intel has never left their war rooms. Until now.

Bryce Paul

Host, Crypto Hedge Fund Summit

P.S. Once these spots fill, this offer disappears.

2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States

The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.

Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

Today's editorial pick for you

4 Gene Editing Stocks to Transform Your Portfolio

Posted On Nov 13, 2025 by Chris Markoch

Gene editing stocks have gone from speculative and theoretical to commercially viable. In December 2023, the United States Food & Drug Administration (FDA) approved the first CRISPR therapies. That's changed the conversation from "if" to "how fast."

How fast may take longer than some investors would like. However, it means there's still an opportunity to invest in gene editing stocks while a long runway exists.

Right now, there are two distinct paths for investors. One is to invest in established pharmaceutical companies. These companies have the financial resources to integrate gene editing into their pipelines by acquiring smaller companies that have done the initial research and development.

The second path is to look for smaller innovators that are pioneering first-generation cures. Some of these companies may be takeover candidates for the future.

Here's a look at four gene editing stocks ranging from blue-chip stability to high-risk, high-reward innovation.

Big Pharma's Quiet Gene Editing Powerhouse

Eli Lilly & Co. (NYSE: LLY) has been one of the best stocks to own in the last three years regardless of the sector. LLY stock has delivered a total return of over 187% in that time, largely stemming from its leadership in GLP-1 drugs for treating type 2 diabetes and obesity.

However, Lilly is also using its robust balance sheet to fund key acquisitions and collaborations in the gene editing space. The company has deals in place with Beam Editing for base editing and Precision BioSciences for in vivo gene editing.

This positions the company in the "how" and the "where" of gene editing. Its current focus is on diseases driven by genetic mutations in the liver and neuromuscular system. The company's candidates are in the early trial stage with completion not expected until 2028 to 2030.

That would be a concern for many smaller firms, but Lilly has the cash flow and global infrastructure to pull it off. Lilly isn't the speculative moonshot that some investors crave, but it's a blue-chip sector leader with yet another reason to believe it will climb even higher.

Commercializing CRSPR First

In the introduction, I mentioned that the FDA approved its first CRISPR therapy in 2023. Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is the large-cap biotech name behind that achievement. Vertex produced Casgevy via its partnership with CRISPR Therapeutics. Casgevy is a first-of-its-kind treatment for sickle cell disease and beta-thalassemia.

Vertex is also exploring in vivo delivery methods and expanding its genetic medicine pipeline beyond hematology to areas that include cystic fibrosis and Type 1 diabetes. That makes it a leader not just in gene editing, but in translational biotechnology, turning molecular innovation into patient outcomes and revenue.

However, investors haven't seen much impact from gene editing on its stock yet. VRTX stock has delivered a total return of around 41% in the past three years. That's not bad by any means, but certainly not what many growth investors seek.

One reason for that is that Casgevy is still in the early commercialization phase. Vertex expects around $100 million in revenue from Casgevy in its 2025 fiscal year, a fraction of the company's total revenue which is expected to be approximately $12 billion.

The Pioneer Has Moved from Science to Revenue

CRISPR Therapeutics (NASDAQ: CRSP) helped invent the modern gene editing era, and now it's starting to reap the rewards. Best known as Vertex's partner on Casgevy, the company is transitioning from a development-stage biotech to a revenue-generating enterprise.

Beyond its approved therapy, CRISPR Therapeutics has a deep pipeline that includes CAR-T oncology programs, as well as in vivo gene editing candidates aimed at muscle and liver disorders.

The company's expertise in CRISPR-Cas9 biology positions it at the forefront of next-generation therapeutics. This includes its investigational CRISPR/Cas9 in vivo gene editing therapy CTX310 that targets angiopoietin-related protein 3 (ANGPTL3) for cardiovascular and cardiometabolic disease.

Still, CRSP stock is a highly volatile moonshot of sorts. The company's fortunes are closely tied to the speed and success of its early pipeline. For investors comfortable with risk, this is a pure-play on CRISPR technology with tangible commercial validation and a long runway for growth.

A Deep-Science Speculative Play

Editas Medicine Inc. (NASDAQ: EDIT) is the most speculative of the gene editing stocks on this list. The company is a pioneer in the CRSIPR field. However, Editas is still a clinical-stage company, which makes it a high-risk investment that may produce a high reward for investors.

The company's lead program, EDIT-401, is a one-time gene editing therapy designed to cut LDL cholesterol. Another candidate, EDIT-301, targets sickle cell disease and beta thalassemia using a unique editing approach that differs from Casgevy's. Early trial data have been promising, showing effective gene correction and robust hemoglobin production in treated patients.

While execution has been uneven in the past, recent management changes and solid clinical results have revived investor optimism. With a market cap under $1 billion, even modest clinical success could deliver outsized returns. For those willing to stomach volatility, Editas is the classic moonshot in genetic medicine.

This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com

Today's Bonus Content: It's Hard to Stay Ahead. This Helps.